On 6 December 2023, the US Food and Drug Administration (FDA) approved China–based manufacturer Bio-Thera Solutions’
bevacizumab biosimilar (BAT1706), Avzivi (bevacizumab-tnjn). This product will be marketed globally by Sandoz.
Bevacizumab is a humanized monoclonal antibody. It inhibits angiogenesis (the formation of new blood vessels) by blocking the action of vascular endothelial growth factor A (VEGF-A). Bevacizumab can therefore slow the growth of new blood vessels in tumours and is used to treat various cancers, including colorectal, lung, breast, glioblastoma, kidney and ovarian [1]. The originator/reference biological is Avastin.
Avzivi, is indicated for treatment of:
· metastatic colorectal cancer
· non-squamous non-small cell lung cancer
· recurrent glioblastoma
· metastatic renal cell carcinoma persistent
· recurrent, or metastatic cervical cancer
· epithelial ovarian, fallopian tube, or primary peritoneal cancer
The FDA approval of Avzivi was based on analytical, non-clinical and clinical data that demonstrated its high similarity to Avastin, with no clinically meaningful differences between the biosimilar product and the reference product.
Avzivi is administered via intravenous infusion over 90 minutes for the first infusion, over 60 minutes for the second infusion if the first infusion is tolerated, and over 30 minutes for subsequent infusions if the second, administered over 60 minutes, is also tolerated.
This bevacizumab copy biological, marketed as Pobevcy (BAT1706), received approval in China in 2021. Three other bevacizumab copy biologicals were also approved in 2021, namely Betta Pharmaceutica and Beijing Mabworks Biotech’s MIL60; TOT BIOPHARM’s Pusintin (朴欣汀, TAB008), and Shanghai Henlius Biotech’s Hanbeitai (汉贝泰, HLX04) [2].
Avzivi will be the fifth bevacizumab biosimilar to enter the market. Biosimilars have approximately 85% of the US bevacizumab market share, and this is Bio-Thera’s second biosimilar approved by the FDA after its Actemra biosimilar, Tofidence [3].
Related article
Progress for bevacizumab copy biologicals from Henlius and Innovent
|
LATIN AMERICAN FORUM
The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. View the latest headline article: La FDA aprueba el biosimilar de bevacizumab Avzivi Browse the news in the Latin American Forum! Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.
FORO LATINOAMERICANO
Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español. Ver el último artículo de cabecera: La FDA aprueba el biosimilar de bevacizumab Avzivi !Explore las noticias en el Foro Latinoamericano! Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.
|
References
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of bevacizumab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Jan 30]. Available from: www.gabionline.net/biosimilars/general/Biosimilars-of-bevacizumab
2. GaBI Online - Generics and Biosimilars Initiative. China approves three bevacizumab copy biologicals [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Jan 30]. Available from: www.gabionline.net/biosimilars/news/china-approves-three-bevacizumab-copy-biologicals
3. GaBI Online - Generics and Biosimilars Initiative. FDA approves first tocilizumab biosimilar Tofidence [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Jan 30]. Available from: www.gabionline.net/biosimilars/news/fda-approves-first-tocilizumab-biosimilar-tofidence
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2024 Pro Pharma Communications International. All Rights Reserved.
0
Post your comment